Predictive and prognostic significance of sodium levels in patients with NSCLC treated by Erlotinib

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00078688" target="_blank" >RIV/00216224:14110/14:00078688 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/14:10285770 RIV/00669806:_____/14:10285770

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Predictive and prognostic significance of sodium levels in patients with NSCLC treated by Erlotinib

Popis výsledku v původním jazyce

Background: Hyponatremia is a well-known phenomenon in cancer patients. The aim of our retrospective study was to assess the relationship of natremia levels to predict treatment with erlotinib and also to assess the prognosis of patients with hyponatremia. Patients and Metods: We analyzed data of 544 patients with advancedstage non-small cell lung cancer (NSCLC) treated with erlotinib. Results: Hyponatremia was measured in 21.5 % of patients before treatment with erlotinib. We found a significant increase in the effectiveness of treatment with erlotinib in patients with normal levels of sodium to hyponatremic patients. Progression-free survival (PFS) and overall survival (OS) were also significantly higher in patients with normal natremia. MultivariateCox model analysis demonstrated that natremia was an independent factor for PFS and OS.

Název v anglickém jazyce

Predictive and prognostic significance of sodium levels in patients with NSCLC treated by Erlotinib

Popis výsledku anglicky

Background: Hyponatremia is a well-known phenomenon in cancer patients. The aim of our retrospective study was to assess the relationship of natremia levels to predict treatment with erlotinib and also to assess the prognosis of patients with hyponatremia. Patients and Metods: We analyzed data of 544 patients with advancedstage non-small cell lung cancer (NSCLC) treated with erlotinib. Results: Hyponatremia was measured in 21.5 % of patients before treatment with erlotinib. We found a significant increase in the effectiveness of treatment with erlotinib in patients with normal levels of sodium to hyponatremic patients. Progression-free survival (PFS) and overall survival (OS) were also significantly higher in patients with normal natremia. MultivariateCox model analysis demonstrated that natremia was an independent factor for PFS and OS.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

5

Strana od-do

7461-7465

Kód UT WoS článku

000346689700077

EID výsledku v databázi Scopus

—